Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

BACKGROUND: Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 (240 weeks) and no TDF resistance through 6 years (288 weeks). AIM: We assessed the efficacy, safety, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Buti, Maria, Tsai, Naoky, Petersen, Joerg, Flisiak, Robert, Gurel, Selim, Krastev, Zahary, Aguilar Schall, Raul, Flaherty, John F., Martins, Eduardo B., Charuworn, Prista, Kitrinos, Kathryn M., Mani Subramanian, G., Gane, Edward, Marcellin, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427621/
https://www.ncbi.nlm.nih.gov/pubmed/25532501
http://dx.doi.org/10.1007/s10620-014-3486-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427621/
https://www.ncbi.nlm.nih.gov/pubmed/25532501
http://dx.doi.org/10.1007/s10620-014-3486-7

Ejemplares similares